Unknown Manufacturer
Icosapent ethyl is an ethyl ester of eicosapentaenoic acid (EPA) that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Icosapent ethyl is an ethyl ester of eicosapentaenoic acid (EPA) that reduces synthesis and enhances clearance of triglycerides that is used to treat patients with severe hypertriglyceridemia.
Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.
作为最大耐受他汀类药物治疗的辅助手段，以降低甘油三酯（TG）水平升高（≥150mg/dL）、已确定的心血管疾病或糖尿病以及2个或更多心血管疾病风险因素的成年患者需要住院治疗的心肌梗死、中风、冠状动脉血运重建和不稳定心绞痛的风险。
2 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
